OESO Newsletter – November 2024

Message to the members of OESO, and to all those who have interest in Esophagology



The **OESO-SEMPIRE**

VIRTUAL EDUCATIONAL CHANNEL 37th meeting

From:

UT MD Anderson Cancer CenterHouston, Texas

Hosted by: **Mehnaz A. Shafi**, MD

Professor of Medicine, Department Chair, Chief, Section of Motility Disorders Gastroenterology, Hepatology and Nutrition

Wednesday, November 27, 2024

• Houston, Texas | Time: 9 - 10:30 am

Europe CET:

Paris: 4 – 5:30 pm
 UK: 3 – 4:30 pm

North America:

West Coast: 7 – 8:30 am
 East Coast: 10 – 11:30 am

South America:

12 noon - 1:30pm

São Paulo:
12 noon – 1:30 pm Buenos
Aires:
12 noon – 1:30 pm
Santiago Chile:

Africa:

Bomet, Kenya: 6 – 7:30 pm Asia: Malaysia,

Kuala Lumpur:
 11 pm – 12:30 am
 (Thu, Nov 28)
 Beijing:
 11 pm – 12:30 am
 (Thu, Nov 28)

Australia:

 Melbourne: 2 – 3:30 am (Thu, Nov 28) Zoom technology applied

Registration is free, but mandatory:

Free registration



Squamous cell dysplasia on superficial esophageal cancer



Presenter of the case:

Anni Chowdhury
 GI Fellow (MDACC)

This case shows the progression of dysplasia over 11 years and the successful treatment with endoscopic therapy and no need for surgery.

68 yr woman with SCCA esophagus 11 years ago. Mass at 20 cm. EUS uT2N1.

- Pathology: poorly differentiated SCCA.
- Stage IIB (T2N1M0) SCC was treated with chemoradiation and chemotherapy with carboplatin and paclitaxel (07/15/2013-08/16/13) with resolution of mass.
- A year later, biopsies showed focal moderate squamous dysplasia.
 Treated with RFA. Since then, she has intermittent resolution of dysplasia only to recur a few months later.
- Most recently, 5 month ago, she had superficial SCCA.
- Again treated with cryotherapy and RFA, with now NED.




Presenter of the case:

Anni Chowdhury
 GI Fellow (MDACC)


40 yr woman with Hodgkin's lymphoma, developed GVHD of the esophagus, also got XRT to esophagus.

- Subsequently developed SCCA esophagus.
- Stage II (uT3 N0 M0) and decision made to start nonsurgical therapy: weekly concurrent chemo-RT with weekly carboplatin AUC 2 and paclitaxel.
- Response to treatment, but chronic dysplasia and chronic intrinsic esophageal stenosis.
- Treated with repeated dilations and RFA to ablate the squamous dysplasia that persisted/recurred after completion of chemotherapy.


Both cases highlight proximal esophageal SCCA, systemic treatment, subsequent dysplasia and chronic strictures, treated with endoscopic therapy.



2 Esophagus at 20 cm



3 Esophagus at 24 cm





Unstained mucosa under Lugol's - 29-30 cm






Unstained mucosa under Lugol's - at 21 cm






Unstained mucosa under Lugol's, 19 cm






19 RFA treatment






1 Upper Third of the Esophagus : Stenosis / Stricture



9 Upper Third of the Esophagus : Stenosis / Stricture




6 Lower Third of the Esophagus



Upper Third of the Esophagus sp dilation



Upper Third of the Esophagus s/p dilation



7 Lower Third of the Esophagus



8 Middle Third of the Esophagus



Upper Third of the Esophagus RFA



13



Upper Third of the Esophagus S/p RFA

Multi-disciplinary panel (MDACC):

- Mehnaz A. **Shafi** (USA)
- Wayne Hofstetter (USA)
- Sun Mi Lee (USA)
- George Triadafilopoulos (USA)

Topics for discussion:

Management of chronic squamous cell dysplasia and early esophageal cancer

- Clinical assessment
- Means of treatment and durability, endoscopic therapy, RFA, cryotherapy, surgery

- Long term follow up, management of chronic strictures
- Review of literature on pathology and endoscopic treatments



Thirty-five Pilot Centers worldwide are currently listed in the network of the OESO-SEMPIRE Platform of Excellence in Esophagology to take part in the program of the **OESO Virtual Educational Channel in Esophagology**.



Such a program is in line with true multi-disciplinarity, the essence of OESO since its creation, and the mission defined by UNESCO in the **Chair of Digital Education** attributed in 2018, to the OESO Foundation at the University of Geneva.



The previous "Staff meeting discussions" were organized in

- 2020: May 28 (Pilot Center of Milan), July 22 (Pilot Center of Stanford), October 3 (Pilot Center of Bomet, Kenya), October 29 (Pilot Center of Beijing), December 10 (Pilot Center of Geneva),
- 2021: January 29 (Pilot Center of Melbourne), February 25 (Pilot Center of Bordeaux), March 19 (Pilot Center of Stanford), April 15 (Pilot Center of Paris), May 26 (Pilot Center of Milan), June 23 (Pilot Center of Sao Paulo), August 21 (Asian Pacific Digestive Week), October 19 (Pilot Center of Mainz), November 22 (Pilot Center of Bordeaux), December 9 (Pilot Center of Geneva),
- 2022: January 20 (Pilot Center of Kota Bharu), February 22 (Pilot Centers of Beijing, Shanghai and Guangzhou), March 24 (Pilot Center of Boston), May 4 (Pilot Centers of Melbourne and Kenya), July 19 (Pilot Center of Kota Bharu), September 23 (Pilot Center of Milwaukee, Wisconsin), October 8 (Pilot Center of Chile), December 14 (Pilot Center of Geneva),
- 2023: January 11 (Pilot Center of Stanford), February 26 (Pilot Center of Malaysia), March 23 (Pilot Center of Boston), May 24 (Pilot Center of Paris), June 1 (Pilot Center of Chile), September 28 (Pilot Center of Milwaukee, WI), November 30 (Pilot Center of Geneva and London) and December 18 (Pilot Center of Zurich),
- 2024: January 24 (Pilot Center of Houston, Texas), February 20 (Pilot Center of Verona), June 5 (Pilot Center of Guangzhou), July 18 (Pilot Center of Bomet) and October 9 (Pilot Center of Hong Kong).



- · Wherever you are in the world,
- Whatever your specialty,

· Whatever your level,

the 37th clinical case of the OESO-SEMPIRE Platform will afford you the opportunity to participate in a global staff meeting dedicated to two challenging topics of esophagology.

Participants from any country can connect to the discussion.

Looking forward to seeing you soon!

Robert Giuli, MD, FACS Professor of Surgery Founder & Deputy Executive Director of OESO

The next 38th clinical case coming up for discussion will be announced on the OESO website and in the next newsletter.

OESO Head Office
2, Bd Pershing
75017 Paris, France
Tel. + 33 (0)1 55 37 90 15
email: michele.liegeon@oeso.org
www.oeso.org



OESO will not supply your Personal Data to any third party for marketing purposes, whether directly or indirectly.

This email has been sent to {{ contact.EMAIL }}You received this email because you are registered by OESO.

<u>Unsubscribe</u>

